Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK MenACWY Conjugate Vaccine Formulations vs Mencevax in Adolescents
NCT00126945Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of meningococcal group A, C, W135 and Y conjugate vaccine in meningococcal disease (5 arms), sponsored by GSK. Primary endpoint: Percentage of serum bactericidal activity (SBA) responders at 1 month. Started Aug 2005; status: completed.
02
Drugs
meningococcal group A, C, W135 and Y conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00126945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126945.